Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 927-248-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- January 2001
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- no
Test material
- Reference substance name:
- 6-(1-bromoethyl)-4-chloro-5-fluoropyrimidine
- Cas Number:
- 188416-28-6
- Molecular formula:
- C6H5BrClFN2
- IUPAC Name:
- 6-(1-bromoethyl)-4-chloro-5-fluoropyrimidine
- Test material form:
- liquid
- Details on test material:
- Amber Oil
Constituent 1
- Specific details on test material used for the study:
- Amber to yellow liquid (batch number 5494/96/I)
Test animals
- Species:
- rat
- Strain:
- CD-1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Animals in the main study were in the weight range of 82 to 118 g and approximately five to seven weeks of age prior to dosing (Day I), All the rats were acclimatised to the experimental environment for a minimum period of at ifive days prior to the start of the study. The rats were allocated without conscious bias to cages within the treatment groups. They were housed in groups of up to five rats of the same sex in metal cages (RS Biotech Sub-Dividable Rodent Cages - polished stainless steel (20cm high x 39cm wide x 39cm long)), The cages were fitted with grid floors to ensure rapid removal of waste material to undertrays. The cages were suspended in mobile stainless steel racks. A standard laboratory rodent diet (Special Diet Services RM1(E) SQC expanded pellet) and drinking water were provided ad libitum. Access to food only was prevented overnight prior to and kw approximately 4 hours after dosing. The batch of diet used for the study was analysed for certain nutrients, possible contaminants and nncro-organisms. Results of routine physical and chemical examination of drinking water, as conducted by the supplier, are made available to Huntingdon Life Sciences Ltd, as quailed)! summaries.
Thermostatic controls were set to maintain a temperature of 22 ±. 3*C, Relative humidity vi,'as not fully controlled but was anticipated to be in the range 30 70%. Temperature and humidity were recorded continuously using a seven day recorder. Actual measurement of these parameters revealed that animal room temperature was in the range 21 to 25°C and relative humidity was in the range 40 - 62%,
Permanent daily recordings of these parameters were made and these are archived with other Departmental raw data. Air exchange was maintained at approximately 18 air changes per hour and lighting was controlled by means of a time switch to provide 12 hours of artificial light (0700 - 1900 hours) in each 24-hour
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- methylcellulose
- Details on oral exposure:
- UK-134,821 was administered initially as supplied at a variable dose volume to achieve the desired dosage and during the latter stage of the study to enhance accuracy at the lower dose concentrations was administered formulated at various w/v concentrations in 1% ‘v/v aqueous methylcellulose and administered at a fixed dose volume of 10 mi/kg boclyweight.
- Doses:
- Initial Study: 500, 2000mg/kg
Main Study: 50, 200 and 500 mg/kg - No. of animals per sex per dose:
- 5 males/5 females
- Control animals:
- yes
- Details on study design:
- A group of 5 males and 5 females received a single oral gavage dose of the test substance at a dose level of 500 mg/kg bodyweight. This dose level was chosen after review of findings in the first phase of preliminary investigations, However, as a result of mortalities at 500 mg/kg a further group of ten rats was dosed at 50 mg/kg bodyweight. This latter dosage was selected after consideration of preliminary study results and in compliance with the test guidelines.
Results and discussion
- Preliminary study:
- In the absence of precise toxicological information a preliminary study was conducted to help define the toxic potential of the test substance and aid in selection oía suitable dosage for the main study, Initially, one female rat was treated at 500 mg/kg and for further clarification one fixt/her female rat was dosed at 2000 mg/kg bodyweight.
The animal treated at 500 mg/kg survived treatment and this dose level was a considered suitable for commencement of the main study. However, as a result of mortalities in the main study at 500 mg/kg further preliminary investigations were undertaken to further define the toxic potential of the test substance. In these further investigations, one female was treated at 50 mg/kg and a further female treated at 200 mg/kg.
Effect levels
- Sex:
- male/female
- Dose descriptor:
- discriminating dose
- Effect level:
- 50 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Cages of rats were checked at least twice daily for mortalities
- Clinical signs:
- other: Animals were observed, soon after dosing and at frequent intervals for the remainder of Day L On subsequent days, surviving animals were observed once in the morning and again at the end of the experimental day (with the exception of the last day of obser
- Gross pathology:
- Macroscopic examination of decedent animals revealed congestive changes (characterised by dark tissue/pr(minent blood vessels) in the subcutaneous tissue, brain, heart, lungs. liver, spleen, kidneys, stomach and along the alimentary tract accompanied by enlargediswollen tissues in the brain, liver and stomach. Gaseousdistension and fluid contents (-yellow/red), food and pallor were noted in the stomach and along the alimentary tract. Pallor was also noted in the urinary bladder. In animals surviving treatment and killed at study termination (Day 15) enlarged, swollen or thickened tissues were noted in the stomach of two females dosed at 50 ml/kg
Applicant's summary and conclusion
- Conclusions:
- The discriminating oral dose to rats of UK-134,821 was indicated to be 50 mg/kg bodyweight
- Executive summary:
This study was performed to assess the acute oral toxicity of UK-134,821 to the rat. The method followed to be compliant with that described in: EEC Methods for the determination of toxicity, Annex. to Directive 92/69/EEC (Official Journal No, 1,383A, 29.12,92), Part B, Methiml B.1 bis, Acute toxicity (oral) fixed dose method. OECD Guideline for Testing of Chemicals No.420 'Acute Oral Toxicity - Fixed Dose Method' Adopted 17 July 1992, A group of ten fasted rats (five males and five females) received a single oral gavage dose of the test substance, administered as supplied at a dose level of 500 mg/kg bodyweight. This dose level was chosen after review of findings in the preliminary study. As a result of mortalities at 500 mg/kg a further group of rats was dosed at 50mg/kg: bodyweight Three males and four females dosed at 500 m g/kg died during the study, All remaining animals treated at 500 mg/kg and animals subsequently dosed at 50 mg/kg were killed as scheduled at study termination (Day 15) and subjected to a macroscopic examination. Clinical signs of reaction to treatment characterised by piloerection (first evident in all rats within nine minutes of dosing) seen in all rats, and accompanied at later intervals on Day 1 or thereafter by hunched posture, waddlinglunstea4 gait, lethargy, pallid extremities, walking on toes, increased salivation, unp,roomed appearance and dark colouring to eyes (notable in all rats at 500 mg/kg). Also observed in one or more animals were, partially closed eyelids, abnormal respiration, abnormal faeces, abnormal urine, increased lacrimation, increased sensitivity to touch, thin appearance, body tremors, clonic convulsion, prostation, blue/cold extremities and swollen abdomen. Recovery in all surviving rats was complete on Day 2 at 50 mg/kg and Day 14 at 500 mg/kg. All surviving rats in the main study were considered to have achieved satisfactory bodyweight gains during the study. Macroscopic examination of the decedents at 500 mg/kg in the main study revealed congestive changes to the majority of tissues and organs with gaseous distension and fluid contents in the stomach and along the alimentary tact. In animals surviving treatment and killed at study termination (Day 15) enlarged, swollen or thickened tissues were noted in the stomach of two females dosed at 50 mg/kg. The discriminating oral dose to 'rats of UK-134,821 was indicated to be 50 mg/kg bodyweight On the basis of findings in this study and in accord with EU hazard classification UK-134,821 will require labelling with the risk phrase .R22 "Harmful if swallowed", in accordance with Commission Directive 93/21,,EEC,
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.